Press Release

Asia Pacific Nucleic Acid Therapeutics CDMO Market to Grow with a CAGR of 13.54% through 2028

Surge in research and development activities is expected to drive the Asia Pacific Nucleic Acid Therapeutics CDMO Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Asia Pacific Nucleic Acid Therapeutics CDMO Market – By Country, Competition, Forecast and Opportunities, 2018-2028F”, the Asia Pacific Nucleic Acid Therapeutics CDMO Market stood at USD966.15 million in 2022 and is anticipated to grow with a CAGR of 13.54% in the forecast period, 2023-2028. The initiatives taken by government based on nucleic acid therapeutics CDMO has led to favorable market conditions for the Asia Pacific Nucleic Acid Therapeutics CDMO Market. Several factors contribute to the growth of various nucleic acid therapeutics CDMO market products.

Policy support is one of the critical areas where Asia Pacific governments have taken proactive initiatives. Recognizing the immense potential of the biopharmaceutical industry, they have developed and implemented favorable policies that provide a wide range of benefits. These include tax incentives, subsidies, and grants, aimed at fostering the growth and innovation of the industry. Notably, these policies extend to the emerging field of nucleic acid therapeutics Contract Development and Manufacturing Organizations (CDMOs), further encouraging their establishment and development within the region.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Asia Pacific Nucleic Acid Therapeutics CDMO Market


In recent years, there has been a significant surge in research and development (R&D) activities focused on nucleic acid therapeutics. This surge has not only brought about exciting breakthroughs but has also led to the discovery of new applications for nucleic acid therapeutics in treating a wide range of diseases. These diseases include various types of cancer and genetic disorders, among others.

As a result of these advancements, the demand for specialized services offered by nucleic acid therapeutics contract development and manufacturing organizations (CDMOs) has skyrocketed. These CDMOs play a crucial role in facilitating the development, scale-up, and manufacturing of nucleic acid therapeutics, thus driving the overall market growth.

The Asia Pacific Nucleic Acid Therapeutics CDMO Market is segmented into product type, technology, regional distribution, and company.

Based on its product type, the custom nucleic acid segment held the largest share in the market. Nucleic acid therapeutics, with their ability to target specific genes or genetic sequences associated with chronic and genetic diseases, offer exciting new possibilities for treatment. These custom-designed nucleic acids provide a novel approach to tackling these conditions, potentially revolutionizing the field of medicine. This immense potential has sparked a surge of interest and investment in the development and application of custom nucleic acid therapeutics, heralding a new era in healthcare innovation.

Based on country, China segment is expected to grow during the forecast period.

One of the key factors that contributes to China's dominance in the nucleic acid therapeutics CDMO market is its large and highly skilled workforce. The country's strong emphasis on education, especially in the sciences, has led to the development of a robust talent pool that actively supports the biopharmaceutical industry. This well-trained workforce enables China to effectively meet the demands of the market and maintain its competitive edge.

In addition to its skilled workforce, the Chinese government has implemented a range of favorable policies aimed at promoting the growth of the biopharmaceutical industry. These policies include generous subsidies and tax incentives, which have not only attracted significant domestic investment but also encouraged foreign companies to invest in China's thriving biopharmaceutical sector. The combination of these policies and investments has created a favorable environment for the industry to flourish, driving innovation and further strengthening China's position in the market.

Major companies operating in Asia Pacific Nucleic Acid Therapeutics CDMO Market are:

  • Asymchem Inc.
  • BioCina Pty Ltd.
  • CMIC HOLDINGS Co., Ltd.
  • Kaneka Corporation
  • Nippon Shkubai Co., Ltd
  • Nitto Inc.
  • ST Pharm Co Ltd


Download Free Sample Report

Customers can also request for 10% free customization on this report


“Growing application of nucleic acid therapeutics CDMO in various end user industries are key drivers of the nucleic acid therapeutics CDMO market. Growth in competitive landscape and presence of well-established companies in the market who are dedicated to enhance their productivity of nucleic acid therapeutics CDMO with every passing year are anticipated to register an impressive growth to Asia Pacific Nucleic Acid Therapeutics CDMO Market in the forecast period.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Asia Pacific Nucleic Acid Therapeutics CDMO Market By Product Type (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Others), By Technology (Column-Based Method, Microarray-Based Method), By Country, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Asia Pacific Nucleic Acid Therapeutics CDMO Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Asia Pacific Nucleic Acid Therapeutics CDMO Market.


Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News